MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/liv.13402

Медицинская библиотека · Liver international : official journal of the International Association for the Study of the Liver · 2017

Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study.

de Vries Elisabeth M G, Färkkilä Martti, Milkiewicz Piotr, Hov Johannes R, Eksteen Bertus, Thorburn Douglas, Chazouillères Olivier, Pares Albert, Nygård Ståle, Gilja Odd H, Wunsch Ewa, Invernizzi Pietro, Carbone Marco, Bernuzzi Francesca, Boberg Kirsten M, Røsjø Helge, Rosenberg William, Beuers Ulrich H, Ponsioen Cyriel Y, Karlsen Tom H, Vesterhus Mette

СтатьяМногоцентровое исследованиеВалидационное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND & AIMS: Biomarkers reflecting disease activity and prognosis in primary sclerosing cholangitis (PSC) have not been firmly established. Enhanced liver fibrosis (ELF) test was previously reported to predict outcome in PSC. We aimed to validate the prognostic utility of ELF test in an independent, multi-centre, retrospective PSC study population.

METHODS

We collected serum samples from PSC patients from seven countries. We estimated rates of transplant-free survival by the Kaplan-Meier method, used Cox proportional hazards regression to explore the association between ELF test and clinical outcome and determined prognostic performance of ELF test by computing the area under the receiver operating characteristic (AUC-ROC) curve.

RESULTS

The final analysis included 534 PSC patients (61% males). Features of autoimmune hepatitis or concomitant inflammatory bowel disease affected 44 (8%) and 379 (71%) patients respectively. ELF test levels were higher in patients reaching the combined endpoint liver transplantation or death (median 10.9 [Interquartile range (IQR): 9.8-12.1]; n=24 deaths, 79 liver transplantations) compared to those censored (8.8 [IQR: 8.0-9.8]); P<.001. ELF test expressed as mild, moderate and severe fibrosis was significantly associated with the risk of reaching the endpoint (P<.001). ELF test independently predicted clinical outcome (Hazard ratio 1.31; 95% confidence interval [1.05-1.65]; P=.018), and enabled good discrimination between PSC patients with and without endpoint (AUC-ROC: 0.79).

CONCLUSION

Our retrospective data validates the predictive utility of ELF test for clinical outcomes in PSC. The clinical utility of biomarkers for fibrosis in patients with PSC should be assessed in prospective patient cohorts.

Для цитирования: de Vries Elisabeth M G, Färkkilä Martti, Milkiewicz Piotr, Hov Johannes R, Eksteen Bertus, Thorburn Douglas, Chazouillères Olivier, Pares Albert, Nygård Ståle, Gilja Odd H, Wunsch Ewa, Invernizzi Pietro, Carbone Marco, Bernuzzi Francesca, Boberg Kirsten M, Røsjø Helge, Rosenberg William, Beuers Ulrich H, Ponsioen Cyriel Y, Karlsen Tom H, Vesterhus Mette. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study.. Liver international : official journal of the International Association for the Study of the Liver. 2017. DOI: 10.1111/liv.13402.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.